The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »
The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »
The News: It has long been a controversial theory about Alzheimer’s disease (AD), often dismissed by experts as a random detour from mainstream research. But a new study by a team that… Read more »
The News: With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, startup Cortexyme Inc. (South San Francisco) has identified a brand-new target and… Read more »
The News: Stepping into ethically and legally uncertain territory, a New York end-of-life agency has approved a new document that lets people stipulate in advance that they don’t want food… Read more »
The News: Long-term consumption of caffeine would worsen the neuropsychiatric symptoms of people with Alzheimer’s disease, according to a study on mice, published in Frontiers in Pharmacology. So far, many studies… Read more »
1. Medical Stock Spotlight 1) Losers far outpaced winners last week with Edge Therapeutics Inc. (Nasdaq:EDGE) nosediving 93% over the week to $1.18. Up until last week, shares of Edge Thera… Read more »
The News: Highly fit women in midlife were nearly 90% less likely to have dementia decades later, a prospective study in Sweden found. Over 44 years of follow-up, the adjusted… Read more »
The News: Hearing loss is a common part of aging, but for some people, it may be a sign of far more serious neurological problems. Researchers in Italy examined two… Read more »
The News: Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trial–which still suggests that it’s… Read more »
